GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » YoY EBITDA Growth
中文

OraSure Technologies (OraSure Technologies) YoY EBITDA Growth

: -42.40% (As of Dec. 2023)
View and export this data going back to 1992. Start your Free Trial

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. OraSure Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -42.40%.

OraSure Technologies's EBITDA per Share for the three months ended in Dec. 2023 was $0.14.

OraSure Technologies YoY EBITDA Growth Historical Data

The historical data trend for OraSure Technologies's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.14 -79.60 -76.47 1,083.33 509.15

OraSure Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 401.20 328.49 157.89 74.52 -42.40

OraSure Technologies YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

OraSure Technologies's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.865-0.142)/ | 0.142 |
=509.15 %

OraSure Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0.144-0.25)/ | 0.25 |
=-42.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OraSure Technologies YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » YoY EBITDA Growth
Comparable Companies
PLSE ANIK SMTI ZJYL UTMD ANGO AKYA STXS HBIO INFU ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B RMD WST XPAR:DIM TSE:4543
Traded in Other Exchanges
EP3:Germany
Address
220 East First Street, Bethlehem, PA, USA, 18015
Website
https://www.orasure.com
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Executives
Kathleen Gallagher Weber officer: Chief Product Officer 220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller officer: VP, Finance and Controller 220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath officer: Chief Financial Officer C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster director ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano director 33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano director 220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton director, officer: President & CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason officer: Interim CFO/SVP IR 1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs director C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin director 21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora director 64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer officer: President of Diagnostics 1 CRESENT PLACE, SHORT HILLS NJ 07078